Neo Ivy Capital Management bought a new position in shares of Catalent, Inc. (NYSE:CTLT - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 17,808 shares of the company's stock, valued at approximately $1,078,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Athos Capital Ltd bought a new stake in shares of Catalent in the 3rd quarter valued at $6,009,000. Dynamic Technology Lab Private Ltd acquired a new position in Catalent in the third quarter valued at $1,131,000. Sumitomo Mitsui Trust Group Inc. boosted its position in Catalent by 3.7% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company's stock valued at $24,550,000 after acquiring an additional 14,373 shares during the last quarter. Quest Partners LLC boosted its position in Catalent by 289.8% during the third quarter. Quest Partners LLC now owns 49,300 shares of the company's stock valued at $2,986,000 after acquiring an additional 36,652 shares during the last quarter. Finally, State Street Corp grew its holdings in Catalent by 1.5% during the 3rd quarter. State Street Corp now owns 7,451,135 shares of the company's stock worth $451,315,000 after acquiring an additional 113,095 shares during the period.
Insider Transactions at Catalent
In related news, Director Michelle R. Ryan sold 2,800 shares of the firm's stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now directly owns 10,835 shares of the company's stock, valued at $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider David Mcerlane sold 1,994 shares of the firm's stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the sale, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,114 shares of company stock worth $305,931 over the last quarter. Corporate insiders own 0.31% of the company's stock.
Catalent Stock Performance
Catalent stock traded down $0.17 during mid-day trading on Thursday, reaching $63.07. 1,743,903 shares of the company's stock were exchanged, compared to its average volume of 2,075,430. The firm has a market capitalization of $11.45 billion, a PE ratio of -27.91, a P/E/G ratio of 2.46 and a beta of 1.15. Catalent, Inc. has a one year low of $37.03 and a one year high of $63.25. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The business's fifty day simple moving average is $60.25 and its 200 day simple moving average is $58.91.
Catalent (NYSE:CTLT - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. Catalent's revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.10) EPS. On average, sell-side analysts expect that Catalent, Inc. will post 0.84 earnings per share for the current year.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on CTLT shares. Baird R W cut Catalent from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. Robert W. Baird reiterated a "neutral" rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. StockNews.com lowered shares of Catalent from a "hold" rating to a "sell" rating in a report on Tuesday. Finally, William Blair reiterated a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating and seven have assigned a hold rating to the stock. According to data from MarketBeat.com, Catalent presently has a consensus rating of "Hold" and a consensus target price of $63.40.
Read Our Latest Stock Analysis on Catalent
Catalent Profile
(
Free Report)
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.
Featured Articles
Before you consider Catalent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalent wasn't on the list.
While Catalent currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.